Literature DB >> 7895178

Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen.

H Brahm1, O Ljunggren, K Larsson, E Lindh, S Ljunghall.   

Abstract

The influence of chronic and acute exposure to parathyroid hormone (PTH) on formation and breakdown of type I collagen, using two recently developed radioimmunoassays for serum PICP (the carboxyterminal propeptide of type I procollagen) and serum ICTP (the carboxyterminal telopeptide of type I collagen), have been evaluated. Fasting morning values were obtained from 18 women with primary hyperparathyroidism (HPT) and an equal number of age-matched, healthy controls. A 24-hour infusion of synthetic human parathyroid hormone (PTH 1-38) was performed in 14 healthy females. The patients with HPT had higher values for serum ICTP than the controls (6.0 +/- 3.0 and 4.1 +/- 2.1 micrograms/liter; P < 0.05), whereas the serum PICP concentrations were not different (170 +/- 72 and 151 +/- 65 micrograms/liter; n.s.). During infusion of PTH in healthy subjects, there was an increase of the serum ICTP concentrations (from 3.6 +/- 1.3 to 4.4 +/- 1.8 micrograms/liter; P < 0.001) whereas those of serum PICP decreased (from 185 +/- 78 to 118 +/- 42 micrograms/liter; P < or = 0.0001). The increase of serum ICTP during infusion of PTH was positively related to the increase of serum calcium and other indices of bone resorption, i.e., fasting urinary excretions of hydroxyproline and calcium. The decrease of serum PICP was also related to the changes of serum ICTP and hydroxyproline in urine, serum calcium, and alkaline phosphatase but not to osteocalcin, an established marker of osteoblastic activity. The findings support the fact that serum ICTP is a valuable method for evaluating bone resorption and is also easy to perform.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7895178     DOI: 10.1007/bf00298553

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  24 in total

1.  Characterization and evaluation of asymptomatic primary hyperparathyroidism.

Authors:  J P Bilezikian; S J Silverberg; E Shane; M Parisien; D W Dempster
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

Review 2.  New biomarkers of bone resorption.

Authors:  D Eyre
Journal:  J Clin Endocrinol Metab       Date:  1992-03       Impact factor: 5.958

3.  Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement.

Authors:  C Joborn; S Ljunghall; K Larsson; E Lindh; T Naessén; L Wide; G Akerström; J Rastad
Journal:  Clin Endocrinol (Oxf)       Date:  1991-05       Impact factor: 3.478

Review 4.  Normal and abnormal bone remodeling in man.

Authors:  R Marcus
Journal:  Annu Rev Med       Date:  1987       Impact factor: 13.739

5.  An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.

Authors:  A B Hodsman; L J Fraher; T Ostbye; J D Adachi; B M Steer
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

6.  Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease.

Authors:  M J Seibel; S P Robins; J P Bilezikian
Journal:  Trends Endocrinol Metab       Date:  1992-09       Impact factor: 12.015

7.  The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones.

Authors:  C Hassager; L T Jensen; J S Johansen; B J Riis; J Melkko; J Pødenphant; L Risteli; C Christiansen; J Risteli
Journal:  Metabolism       Date:  1991-02       Impact factor: 8.694

8.  Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases.

Authors:  P R Ebeling; J M Peterson; B L Riggs
Journal:  J Bone Miner Res       Date:  1992-11       Impact factor: 6.741

9.  Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease.

Authors:  R J Duda; J F O'Brien; J A Katzmann; J M Peterson; K G Mann; B L Riggs
Journal:  J Clin Endocrinol Metab       Date:  1988-05       Impact factor: 5.958

10.  Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase.

Authors:  A M Parfitt; L S Simon; A R Villanueva; S M Krane
Journal:  J Bone Miner Res       Date:  1987-10       Impact factor: 6.741

View more
  1 in total

1.  The effects of brisk walking on markers of bone and calcium metabolism in postmenopausal women.

Authors:  K Thorsen; A Kristoffersson; R Lorentzon
Journal:  Calcif Tissue Int       Date:  1996-04       Impact factor: 4.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.